STK25 inhibits cancer‐associated fibroblast activation to overcome cetuximab resistance in colorectal cancer
Clinical and Translational Medicine · 2026
DOI: 10.1002/ctm2.70678 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2026. Verfasst von Yifan Hou und 17 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery IV, Peking University Can…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Cancer-Associated Fibroblasts, Intracellular Signaling Peptides and Proteins, Hippo Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Postdoctoral Fellowship Program of CPSF, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Background
Cancer‐associated fibroblasts (CAFs) within the tumour microenvironment play a pivotal role in colorectal cancer (CRC) progression and therapeutic resistance. Serine/threonine protein kinase 25 (STK25) exerts multiple roles in tumourigenesis; however, its role in mediating tumour–stroma crosstalk remains largely unexplored.
Methods
Primary CAFs were isolated from CRC patient tissues and characterised to confirm their identity. The effects of STK25 expression on CAF activity and CAF‐mediated tumour progression were evaluated both in vitro and in vivo. Western blot, qRT‐PCR, ChIP and dual‐luciferase reporter assays were performed to elucidate the mechanism by which STK25 regulated CAF activation. Moreover, the effect of STK25 expression on CAF‐induced cetuximab resistance was assessed in vitro and in vivo. The clinical significance of STK25 expression was determined in CRC patient tissues, tissue microarrays and patient‐derived organoids.
Results
Knockdown of STK25 in CRC cells enhanced CAF proliferation, migration and activation, whereas its overexpression exhibited the opposite effect. STK25‐knockdown‐mediated CAF activation subsequently promoted CRC cell proliferation and metastasis. Moreover, STK25 depletion combined with CAFs significantly enhanced CRC tumour growth in vivo. Mechanistically, STK25 deficiency activated the NF‐κB pathway, leading to p50 phosphorylation which directly bound to the AREG promoter, thereby transcriptionally up‐regulating AREG expression. In addition, STK25‐regulated AREG/EGFR axis mediated the crosstalk between CRC cells and CAFs. More importantly, CAFs conferred resistance to the anti‐EGFR antibody cetuximab, which could be reversed either by STK25 overexpression or by AREG‐neutralising antibody treatment. Clinically, low STK25 expression correlated with elevated CAFs marker levels and poor cetuximab response in CRC patients.
Conclusions
Our findings identified STK25 as a critical regulator of the NF‐κB/AREG/EGFR axis in tumour–CAF communication and highlight its potential as a therapeutic target for overcoming CAF‐induced cetuximab resistance in CRC. Key points STK25 deficiency enhanced CAF‐mediated CRC growth via the NF‐κB/AREG/EGFR axis. STK25 overexpression or AREG antibody overcame CAF‐mediated cetuximab resistance. CRC patients with high STK25 and low CAFs marker levels might benefit from cetuximab treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery IV, Peking University Cancer Hospital & Institute, Beijing, China.
- Department of Education, Peking University Third Hospital, Beijing, China.
- Department of Clinical Medicine, Capital Medical University, Beijing, China.
- Department of Gastrointestinal Surgery, Peking University Cancer Hospital (Inner Mongolia Campus) & Affiliated Cancer Hospital of Inner Mongolia Medical University, Hohhot, China.
- State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Gastrointestinal Surgery IV, Peking University Cancer Hospital & Institute, Beijing, China.
ORCID-Profile: Xiangqian Su
Förderung
- National Natural Science Foundation of China
- Postdoctoral Fellowship Program of CPSF
- China Postdoctoral Science Foundation
- Science Foundation of Peking University Cancer Hospital
- Clinical Research Fund for Distinguished Young Scholars of Beijing Cancer Hospital
- Natural Science Foundation of Inner Mongolia Autonomous Region of China
- Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education
Zitieren
APA
Hou, Y., Chen, J., Hao, H., Song, T., Song, L., Xing, P., Weng, K., Ran, Y., Yang, X., Qiao, X., Chen, J., Yao, R., Yang, H., Chen, L., Di, J., Xu, K., Su, X., & Jiang, B. (2026). STK25 inhibits cancer‐associated fibroblast activation to overcome cetuximab resistance in colorectal cancer. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70678
Vancouver
Hou Y, Chen J, Hao H, Song T, Song L, Xing P, et al. STK25 inhibits cancer‐associated fibroblast activation to overcome cetuximab resistance in colorectal cancer. Clinical and Translational Medicine. 2026. doi:10.1002/ctm2.70678
BibTeX
@article{Hou2026,
author = {Hou, Yifan and Chen, Jiangbo and Hao, Hao and Song, Tongkun and Song, Lin and Xing, Pu and Weng, Kai and Ran, Yumeng and Yang, Xinying and Qiao, Xiaowen and Chen, Jie and Yao, Ruibin and Yang, Hong and Chen, Lei and Di, Jiabo and Xu, Kai and Su, Xiangqian and Jiang, Beihai},
title = {STK25 inhibits cancer‐associated fibroblast activation to overcome cetuximab resistance in colorectal cancer},
journal = {Clinical and Translational Medicine},
year = {2026},
doi = {10.1002/ctm2.70678}
}
EUVIMED